Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

Chronic Hypoparathryroidism Tied to Kidney Complications: Study

Patients with long-lasting hypoparathyroidism in Sweden are over three times more likely than healthy individuals to develop kidney complications such as chronic kidney disease and kidney stones, and this may translate into more frequent hospital admissions, a study found. The study, “Kidney Complications and Hospitalization in Patients with…

PTH Levels Help Predict Recovery 6 Months After Thyroid Surgery

Late recovery — longer than six months — from post-surgery hypoparathyroidism is not uncommon, and having levels of parathyroid hormone (PTH) within the normal range may indicate whether patients are more likely to recover, a study found. “PTH is a useful biomarker in predicting long-term recovery of parathyroid function,”…

Hypoparathyroidism Tied to Buildup of Pressure in Young Girl’s Skull

Hypoparathyroidism caused a buildup of pressure around a young girl’s brain, according to a report from Italy focused on a difficult diagnosis. “Our case report is of particular interest, since the child did not present with typical neurological hypoparathyroidism symptoms,” the researchers wrote. “Therefore, we recommend that hypoparathyroidism should…

ATA Criteria Useful for Grouping Patients by Hypocalcemia Symptoms

The American Thyroid Association (ATA) diagnostic criteria for postoperative hypoparathyroidism are useful to doctors in grouping patients based on symptoms, which could help in managing the disease, a study reported. “However,” the researchers wrote, differentiating patients in this way “may underestimate the actual incidence,” or the number of…

Visen Set to Start Phase 3 Trial of TransCon PTH in China

Visen Pharmaceuticals has obtained regulatory clearance to start the PaTHway China Trial, a Phase 3 study of TransCon PTH as a hormone replacement therapy for people with hypoparathyroidism in China. The approval from China’s Center for Drug Evaluation of the National Medical Products Administration came on June 1,…